VM VIA MEDICA

HOW TO DO

Post percutaneous coronary intervention antiplatelet therapy: Current perceptions, prospects and perplexity

Sadip Pant[1], Pritam Neupane[2], Ramesh KC[3], Murari Barakoti[4]

[1]Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
[2]Department of Pulmonary and Critical Care, Medical College of Georgia, Augusta, GA, USA
[3]Department of Internal Medicine, Mercy Catholic Medical Center, Philadelphia, PA, USA
[4]Department of Cardiology, Institute of Medicine, Kathmandu, Nepal

Abstract

Dual antiplatelet therapy (DAT) has become standard care for patients undergoing percutaneous coronary intervention (PCI). Following balloon injury and stent placement, the intima at the site is distressed, resulting in the activation of coagulation cascade and platelets. In the case of bare metal stents (BMS), it takes six to eight weeks for the stent surface to be covered with neointima. However, in the case of a drug-eluting stent (DES), the process of healing is delayed and neointima may not form for months or even years. To prevent the formation of platelet thrombi, dual antiplatelet therapy is given as a combination of aspirin and clopidogrel for three months in a case of BMS and for a minimum of one year in a case of DES. A prolonged duration of therapy is often required for a subset of patients who are highly prone to thrombus formation. During most non-cardiac surgeries, dual antiplatelet therapy should be continued if bleeding can be directly controlled and excessive bleeding will have no adverse effect on the outcome of surgery. Prasugrel, another thienopyridine, is more potent and faster acting than clopidogrel, and is therefore of great value in cases of acute coronary syndrome during PCI, particularly in diabetics. Triple drug therapy, by adding cilastozol, is reserved for some selected thrombotic lesions. Ticagrelor and cangrelor are two new antiplatelet agents undergoing various clinical trials. (Cardiol J 2011; 18, 6: 712–717)

Key words: percutaneous coronary intervention, dual antiplatelet therapy, restenosis

Introduction

Percutaneous coronary intervention (PCI) using a bare metal stent (BMS) or a drug-eluting stent (DES) has become a widely accepted treatment for obstructive coronary artery disease (CAD). The procedure of PCI inflicts balloon injury to the site of the lesion, leading to activation of the coagulation cascade which may lead to acute and subacute thrombosis (SAT) [1]. Placement of the stent further complicates the local coagulation process with higher chances of thrombosis over the metal surface. Aggressive anticoagulation regimens have been shown to minimize the stent thrombosis rate. However, such an approach can also result in higher rates of vascular complications, in particular bleeding [2]. There has been ample clinical research in the last decade to unravel the optimal antiplatelet therapy, their dosage, the duration of such therapy and related issues in order to reduce the thrombotic complications of PCI.

Address for correspondence: Sadip Pant, MD, Department of Internal Medicine, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, 72205 AR, USA, tel: 757 263 9195, e-mail: sadippant@hotmail.com

Thrombotic complications of PCI

The most dreaded complications following PCI are SAT, late stent thrombosis (LST) and very late stent thrombosis (VLST). Thrombosis occurring within 30 days is called SAT; thrombosis occurring after 30 days to one year is called late stent thrombosis; and that occurring more than one year later is called very LST [3, 4].The complication can result in fatal myocardial infarction (MI) in as many as 45% of cases [5]. Vascular injury caused by high pressure balloon dilatation and deployment of a stent leads to adherence of activated platelets at the site of injury. There is release of adenosine diphosphate (ADP), tromboxane A2 and other procoagulative factors. Release of these factors further leads to platelet aggregation and the formation of platelet-rich thrombi. The process starts almost simultaneously with balloon dilatation and stent placement. Exposure of blood coagulation components, particularly activated platelets, to the bare metal surface of the stent makes the area vulnerable to thrombosis until the stent surface gets covered with a neointima [6]. In a case of BMS, the neointima begins to form within a couple of weeks and the chances of thrombus formation keep on reducing until the stent is fully covered with neointima within eight to ten weeks. In a case of BMS, it is very uncommon to encounter thrombosis beyond this period [7–9]. DESs are very effective in reducing the chances of restenosis and thereby the need for reintervention. They do so by reducing neointimal proliferation. However, the process of stent endothelialization also gets delayed by several months or years [6]. Furthermore, sirolimus and paclitaxel induced expression of tissue factor in the DES stented lesion may kick off the coagulation cascade [6]. Finally, the polymer coating on the DES can provoke infiltration of eosinophilic cells in the vessel wall suggestive of hypersensitivity reaction, and this might contribute to a prothrombotic milieu [10].

In autopsy specimens taken from patients who have died of LST or VLST, the stents have been found to be inadequately covered with neointima with thrombi over bare metal surface of the stent [10, 11].

Evolution of dual antiplatelet therapy

In previous decades, aspirin alone in small to large doses, and subsequently in combination with coumadin, was tried but found to be ineffective in terms of reducing the incidence of SAT [12, 13]. A dual antiplatelet combination with ticlopidine, a thienopyridine derivative, proved reasonably effective in reducing the incidence of SAT compared to aspirin alone [12, 13]. However, the bone marrow suppression associated with ticlopidine clearly required another effective agent to replace ticlopidine in the combination. Clopidogrel was introduced in the late 1990s. Higher efficacy and diminished likelihood of bone marrow suppression made this new thienopyridine compound very popular. Soon, clopidogrel with aspirin became the standard care for patients undergoing PCI [14–17].

Concerns regarding clopidogrel use

Duration of use

Current guidelines of clopidogrel use in BMS patients are clear and robust (Grade 1A evidence). Clopidogrel 75 mg a day, along with aspirin 150 mg, is given for a minimum of one month and ideally up to 12 months, unless the patient is prone to bleeding [18, 19]. In patients who undergo PCI for ACS, a minimum 12 month duration is recommended (Grade 1B evidence) [18, 19]. The recommendations for DES have varied over the last few years. The earliest studies recommended only three months of dual antiplatelet therapy (DAT) following a sirolimus coated stent and six months following a paclitaxel coated stent [20]. However, several case reports of LST and VLST due to delayed healing, and autopsy confirmations of inadequate neointimal coverage for several months and years have led to confusion regarding the period for which DAT should be continued following DES implantation [18, 19]. The ACC/AHA guidelines recommended a minimum of 12 months of DAT for patients who receive DES (Grade 1B evidence) [18, 19]. DAT for longer than 12 months, and perhaps indefinitely, after DES is considered necessary in a subset of patients when antithrombotic benefit appears to exceed the risk for bleeding. This subset includes patients with minimal risk of gastrointestinal or cerebral bleeding and at increased risk of late stent thrombosis (such as those with prior brachytherapy, reduced left ventricular systolic function, complex PCI, or suboptimal procedure outcome), or in whom stent thrombosis could be catastrophic (PCI of left main or proximal left anterior descending coronary arteries). Aspirin at a dose of 75 to 162 mg/day should be continued indefinitely in all stented patients (Grade 1A evidence) [18, 19].

Clopidogrel resistance

Depending on the definition used and the laboratory assay employed to measure resistance, between 4% and 68% of patients do not show adequate

Table 1. GRAVITAS: Primary end-point.

End-point	High-dose clopidogrel	Standard-dose clopidogrel	Hazard ratio (95% CI)	P
CV death/MI/stent thrombosis	2.3%	2.3%	1.01 (0.58–1.76)	0.98

CV — cardiovascular; MI — myocardial infarction

Table 2. GRAVITAS: Bleeding results.

Outcome	High-dose clopidogrel	Standard-dose clopidogrel	P
GUSTO severe/moderate bleeding	1.4%	2.3%	0.10
Any GUSTO bleeding	12.0%	10.2%	0.18

Table 3. GRAVITAS: Percentage of patients with persistently high platelet reactivity at 30 days.

Platelet reactivity units (PRU)	High-dose clopidogrel	Standard-dose clopidogrel	P
≥ 230	62%	40%	< 0.001

response to platelet [21–27]. Clopidogrel resistance has been attributed to variation in gut absorption, variation in metabolism via CYP450 enzyme, variation in the combination with its platelet P2Y12 receptor, and possibly interaction with other drugs, especially proton pump inhibitors (PPIs) [25]. Because of partial or complete resistance, various dose schedules, particularly the administration of loading dose, have been recommended. A 600 mg loading dose of clopidogrel produces a greater maximal antiplatelet effect, an earlier antiplatelet effect, and reduces the likelihood of clopidogrel resistance [28––34]. There was no benefit found on cardiovascular (CV) outcomes or stent thrombosis with a double dose of clopidogrel in patients receiving DES with high residual platelet activity on a regular clopidogrel dose in the GRAVITAS trial [35]. In this trial, 5,429 patients on a regular dose of clopidogrel underwent platelet-function tests with the Verify-Now assay (Accumetrics, San Diego, CA, USA) 12 to 24 hours after PCI; 41% of the patients from this pool had high residual platelet reactivity (platelet reactivity units or PRU ≥ 230). They were randomized to continue on the 75 mg regular clopidogrel dosage arm or to receive another 600 mg loading dose and a higher maintenance dose of 150 mg daily arm. Baseline characteristics of the samples revealed that most patients were at relatively low risk, with 80% having stable CAD. There was an identical composite end-point of CV death/

/MI/stent thrombosis in both the groups (2.3%) at six month follow-up (Table 1).

Stent thrombosis occurred in 0.5% of the high-dose group compared to 0.7% of the standard-dose group but the difference was not statistically significant. There was also no difference in bleeding between the two groups (Table 2).

The absolute platelet reactivity was reduced from an average of about 280 PRU at baseline to 200 PRU in the high-dose clopidogrel group, in comparison to 240 PRU in the standard-dose group at 30 days. This was a modest, albeit statistically significant, reduction in PRU. Results at six months were virtually the same as those at three months (Table 3) [36].

TRIGGER-PCI had a similar trial design to GRAVITAS but compared clopidogrel with prasugrel based on platelet-reactivity testing in stable CAD patients post-stenting. The trial was halted prematurely and hence could not render any noteworthy information on whether a significant gain in primary CV outcome could be achieved by adding more effective antiplatelet therapy.

Finally, another trial, TRILOGY AS, comparing clopidogrel and prasugrel, is still ongoing in patients with acute coronary syndrome (ACS).

Interaction with proton pump inhibitors

Patients who are on DAT are prescribed PPI because aspirin can be responsible for gastritis and, in combination with clopidogrel, there are concerns

about gastrointestinal bleeding. A possible but un-proven clinical effect of PPIs on the protection afforded by clopidogrel has been evaluated in a large number of studies, with varying and often conflicting conclusions [36–43]. The only large scale randomized trial of omeprazole *vs* placebo in clopidogrel users, the CONGENT trial, showed no significant difference in CV events (HR 0.99; 95% CI 0.68–1.44) along with a significant reduction in GI events (HR 0.34; 95% CI 0.18–0.63). However, this trial had to be terminated early because of lack of availability of continued funding by the sponsor. As a result, only 3,873 of the planned sample size of 5,000 were enrolled and there were only 109 primary CV end-points [44]. In November 2009, the US Food and Drug Administration stated that the concomitant use of omeprazole and clopidogrel should be avoided because of the effect on clopidogrel metabolism and therefore its antiplatelet activity [45]. Since the level of inhibition among other PPIs varies, it is unknown to what extent other PPIs may interfere with clopidogrel. However, esomeprazole, a PPI that is a component of omeprazole, inhibits CYP2C19 and should also be avoided in combination with clopidogrel. While the current state of knowledge does not validate the statement that PPIs are associated with clinical CV events among clopidogrel users, further randomized trials are clearly needed to draw up more concrete evidence-based guidelines.

Dual antiplatelet therapy during non-cardiac surgery

For elective non-cardiac surgery, DAT should be continued for at least the minimum duration recommended for each stent type. However, in cases where surgery is emergent, one has to evaluate the risk of bleeding during the surgical procedure. In most surgery where the chances of bleeding are less, or the bleeding can be controlled directly during surgery, it is advisable not to discontinue DAT [46]. In some procedures, such as hip, brain or spinal surgery, if needed as emergency procedures when bleeding may be difficult to control and could have adverse effects on the surgical outcomes, it may be better to discontinue one of the two agents. Thienopyridine may be discontinued for as brief a period as possible and aspirin may be continued uninterrupted if the 12 month period of DAT is not finished [46]. It is recommended that for any dental treatment, including extraction, or any other major surgery including open abdominal surgery where there is direct access to control bleeding, DAT may be continued weighing the risk of some

extra bleed that one may encounter [46]. The concept of bridging a gap in thienopyridine therapy using an intravenous glycoprotein IIb/IIIa inhibitor such as tirofiban is under investigation [47].

Future paradigms in antiplatelet therapy

Triple antiplatelet therapy

Triple antiplatelet therapy i.e. aspirin, clopidogrel and cilostazol, compared to dual antiplatelet therapy i.e. aspirin and clopidogrel, has shown a lower rate of adverse CV outcomes after stent placement in patients with either stable or unstable coronary disease in several studies [48–51].

This holds true for both short- and long-term outcomes without significant difference in the rate of bleeding. In the recent CILON-T study, a combination of aspirin, clopidogrel and cilastozol in PCI for acute MI was not associated with a significant reduction in clinical outcomes after DES placement compared to the standard DAT [52]. However, the addition of cilostazol did improve post-treatment platelet reactivity as measured by P2Y12-receptor reaction units (PRU). Multiple studies have shown an association between platelet activity and outcomes. Even in the CILON-T trial, patients in the lowest tertile of platelet reactivity (PRU values of 0 to 184 U) had zero clinical events (cardiac death, non-fatal MI, ischemic stroke). We are yet to see if changing therapy based on the functional platelet knowledge changes clinical outcomes, and whether platelet reactivity is a better guide to monitoring therapy among post-PCI patients.

Newer antiplatelet agents

Prasugrel is a newer drug which binds irreversibly to the P2Y12 platelet receptor, as does clopidogrel. However, it has several distinct advantages over clopidogrel. It has a more rapid onset of action (an incredibly beneficial property whenever emergency PCI is contemplated) and is able to achieve higher degrees of platelet inhibition than clopidogrel, while having a comparable rate of significant bleeding [53]. Furthermore, human polymorphisms in gene encoding CYP450 system affect prasugrel therapy to a lesser extent; hence, platelet activity is suppressed in a larger number of patients than clopidogrel.

TRITON-TIMI 38, a pivotal trial for prasugrel, analyzed 13,608 patients with moderate to high risk ACS undergoing PCI randomized to receive prasugrel with aspirin in one arm and standard DAT in the other [54]. At an average follow-up of 14.5 months, prasugrel was associated with a significant 2.2%

absolute reduction and a 19% relative reduction in death, non-fatal MI and non-fatal stroke. Diabetics appear to derive greater benefit. The *post hoc* analysis revealed three subsets of patients who showed less net clinical benefit and increased risk of bleeding. These include patients with a history of stroke or transient ischemic attack, those above 75 years, and those weighing less than 60 kg. Based on the TRITON-TIMI 38 results, patients in whom prasugrel should be considered include those with STEMI and NSTEMI in whom a decision has been made to withhold thienopyridine therapy until after diagnostic coronary angiography. Further, it may be considered an alternative to clopidogrel in moderate or high risk ACS undergoing PCI without the aforementioned contraindications [54]. Overall, prasugrel appears to be an important advance in antiplatelet therapy.

Ticagrelor and cangrelor: Two newer antiplatelet agents

Ticagrelor differs from the thienopyridines in that it binds reversibly, rather than irreversibly, with the P2Y12 platelet receptor and has a more rapid onset of action than clopidogrel [55]. It belongs to a new chemical class of antiplatelet agents, the cyclopentyltriazolopyrimidines. In a similar fashion to prasugrel, treatment with ticagrelor leads to more intense platelet inhibition than clopidogrel [56]. In the original PLATO trial of dual antiplatelet treatment in ACS, ticagrelor significantly reduced the primary outcome of vascular death, non-fatal MI, and non-fatal stroke compared to clopidogrel (absolute risk 9.8% *vs* 11.7%; hazard ratio 0.84, 95% CI 0.77–0.92) [56]. Further, in a subgroup analysis of 5,216 (28%) PLATO recruits who were intended for non-invasive management at the time of admission, James et al. [57] found no higher risk of bleeding. Ticagrelor now has a class 1 recommendation in the European revascularization guidelines for use in combination with aspirin for the invasive management of ACS [58]. A similar recommendation will perhaps soon follow for non-invasive management [59]. Cangrelor is an intravenous non-thienopyridine P2Y12 receptor blocker that has not been shown to be superior to clopidogrel in patients with ACS undergoing PCI [37, 60].

Acknowledgements

References

1. Lee MS, David EM, Makkar RR, Wilentz JR. Molecular and cellular basis of restenosis after percutaneous coronary intervention: The intertwining roles of platelets, leukocytes, and the coagulation–fibrinolysis system. J Pathol, 2004; 203: 861–870.
2. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med, 1994; 331: 489–495.
3. Spaulding C, Daemen J, Boersma E et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 2007; 356: 989–997.
4. Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation, 2007; 115: 2344–2351.
5. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005; 293: 2126–2130.
6. Lüscher TF, Steffel J, Eberli FR et al. Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation, 2007; 115: 1051–1058.
7. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: A special risk for late stent thrombosis. J Am Coll Cardiol, 2005; 45:456–459.
8. Scheller B, Hennen B, Pohl A et al. Acute and subacute stent occlusion: Risk-reduction by ionic contrast media. Eur Heart J, 2001; 22: 385–391.
9. Ellis SG, Colombo A, Grube E et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: A TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to three years. J Am Coll Cardiol, 2007; 49: 1043–1051.
10. Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation, 2007; 115: 2435–2441.
11. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol, 2006; 48: 193–202.
12. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med, 1998; 339: 1665–1671.
13. Schömig A, Neumann FJ, Walter H et al. Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol, 1997; 29: 28–34.
14. Moussa I, Oetgen M, Roubin G et al. Effectiveness of clopidogrel and aspirin *versus* ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation, 1999; 99: 2364–2366.
15. Bertrand ME, Rupprecht HJ, Urban P et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation, 2000; 102: 624.
16. Bhatt DL, Bertrand ME, Berger PB et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol, 2002; 39: 9–14.
17. Mueller C, Roskamm H, Neumann FJ et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol, 2003; 41: 969–973.
18. Becker RC, Meade TW, Berger PB et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008; 133: 776S.
19. Kushner FG, Hand M, Smith SC Jr et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guidelines and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guidelines and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2009; 54: 2205–2241.
20. Anderson J, Adams C, Antman E et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-

-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol, 2007; 50: e1 [available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007)].

21. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug 'resistance'. Part 1: Mechanisms and clinical measurements. Nat Rev Cardiol, 2009; 6: 273–282.
22. Lev EI, Patel RT, Maresh KJ et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance. J Am Coll Cardiol, 2006; 47: 27–33.
23. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 2003; 107: 2908–2913.
24. Bellemain-Appaix A, Montalescot G, Silvain J et al. Slow response to clopidogrel predicts low response. J Am Coll Cardiol, 2010; 55: 815–822.
25. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol, 2005; 45: 1157–1164.
26. Müller I, Besta F, Schulz C et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost, 2003; 89: 783–787.
27. Campo G, Valgimigli M, Gemmati D et al. Poor responsiveness to clopidogrel: Drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol, 2007; 50: 1132–1137.
28. Patti G, Colonna G, Pasceri V et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation, 2005; 111: 2099.
29. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol, 2008; 51: 1404.
30. L'Allier PL, Ducrocq G, Pranno N et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: Results from the PREPAIR randomized study. J Am Coll Cardiol, 2008; 51: 1066–1072.
31. Gladding P, Webster M, Zeng I et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: The PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Cardiovasc Interv, 2008; 1: 612–619.
32. Gladding P, Webster M, Zeng I et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: An analysis from the PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Cardiovasc Interv, 2008; 1: 620–627.
33. Aleil B, Jacquemin L, De Poli F et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: Results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. J Am Coll Cardiol Cardiovasc Interv, 2008; 1: 631.
34. Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol, 2010; 56: 1630–1636.
35. Price MJ, Berger PB, Teirstein PS et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA, 2011; 305: 1097–1105.
36. Oyetayo OO, Talbert RL. Proton pump inhibitors and clopidogrel: Is it a significant drug interaction? Expert Opin Drug Saf, 2010; 9: 593–602.
37. Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med, 2010; 363: 1909–1917.
38. Siller-Matula JM, Jilma B, Schrör K et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: A systematic review and meta-analysis. J Thromb Haemost, 2010; 8: 2624–2641.
39. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ, 2009; 180: 713–718.
40. Aubert RE, Epstein RS, Teagarden JR et al. Proton pump inhibitors effect on clopidogrel effectiveness: The Clopidogrel Medco Outcomes Study. Circulation, 2008; 118: S815 (abstract).

41. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA, 2009; 301: 937–944.
42. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation, 2009; 120: 2322–2329.
43. Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol, 2010; 33: 168––171.
44. Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med, 2010; 363: 1909–1917.
45. Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Available on the FDA website at: www.fda.gov/Drugs/DrugSafety (accessed on November 18, 2009).
46. Fleisher LA, Beckman JA, Brown KA et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation, 2009; 120: e169.
47. Savonitto S, D'Urbano M, Caracciolo M et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: A phase II study of «bridging» antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth, 2010; 104: 285.
48. Lee SW, Park SW, Hong MK et al. Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis. J Am Coll Cardiol, 2005; 46: 1833–1837.
49. Han Y, Li Y, Wang S et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study. Am Heart J, 2009; 157: 733–739.
50. Chen KY, Rha SW, Li YJ et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation, 2009; 119: 3207–3214.
51. Lee SW, Park SW, Yun SC et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE) registry. Am Heart J, 2010; 159: 284.
52. Kim H. LBCT II. CILON-T: Triple antiplatelet therapy associated with improved platelet reactivity. Presented at American College of Cardiology 59th Annual Scientific Sessions; March 13–16, 2010; Atlanta, GA, USA.
53. Wiviott SD, Antman EM, Winters KJ et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation, 2005; 111: 3366–3381.
54. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007; 357: 2001–2015.
55. Schömig A. Ticagrelor: Is there need for a new player in the antiplatelet-therapy field? N Engl J Med, 2009; 361: 1108––1111.
56. Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009; 361:1045–1057.
57. James SK, Roe MT, Cannon CP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: Substudy from the Prospective Randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ, 2011; 342: d3527.
58. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2010; 20: 2501–2555.
59. Timmis A. Non-interventional management of acute coronary syndromes. BMJ, 2011; 342: d3263.
60. Harrington RA, Stone GW, McNulty S et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med, 2009; 361: 2318–2329.